SP
The startup develops in-vitro diagnostic assays that utilize a panel of biomarkers to assess the risk of severe dengue in patients. This technology enables healthcare professionals to deliver personalized therapeutic interventions based on precise diagnostic results.
Updated 3 months ago
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops in-vitro diagnostic assays that utilize a panel of biomarkers to assess the risk of severe dengue in patients. This technology enables healthcare professionals to deliver personalized therapeutic interventions based on precise diagnostic results.